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In view of our
changing
environment, it
seems prudent to
explain in detail
any divergence
between
preliminary
presentations and
published articles,
and between
proposed protocol
and reported
results, even if the
details seem
excessive.An issue has recently arisen at the Journal that has implications well beyond a few spe-ciﬁc papers referenced in Letters to the Editor. The core of the issue relates to differ-ences in data for a given project between the publishedmanuscript and prior versions in
abstract form, or even oral presentations. Inquiries concerning several speciﬁc papers sought
clariﬁcation of apparent discrepancies between such various presentations in order to fully
understand the ﬁndings. However, the questions that were posed invariably raised the unspoken
possibility of bias in thehandlingof the data published.Although seemingly atﬁrst blush a simple
matter to address, the complexity and implications of this issue were sufﬁcient to provoke
considerable discussion and varied opinions at conferences of journal editors at the European
Society of Cardiology meeting. It seems clear that it will be important to reach a general
agreement on how to handle such matters in the future.
When I ﬁrst entered the arena of academic medicine over 35 years ago, it was not at all
uncommon to submit partially completed studies for abstract presentation, or to include such
data in invited lectures. In terms of abstracts, it was assumed that more complete data would
be obtained in the interval before the meeting, and accepted that the ﬁndings might change
considerably. I distinctly recall submitting one abstract based on 8 experiments that was
essentially entitled “A Is Greater Than B.” By the time of presentation we had doubled our
sample and now found that B was greater than A. Our ﬁrst slide, therefore, contained the
initial title of our abstract with a line through it, and a second title below describing the
actual ﬁndings. No one seemed to ﬁnd this the least bit objectionable. Not only was it
accepted that abstract ﬁndings might change, but in fact, one of the assumed purposes of
abstract talks was to obtain constructive criticism so as to improve the research project going
forward. A similar approach was taken to preliminary data included in invited lectures.
Although considerable latitude has always been given to preliminary presentations of data,
there have also been bounds beyond which questions would arise. Concerns were nearly never
expressed when the results of new experiments were added to preliminary data, or when
a change in protocol yielded different ﬁndings. However, when the number of experiments or
patients decreased markedly between abstract and paper, or especially when the number of
deaths or adverse events were substantially less, or when measurements presented in the
preliminary version were omitted in the ﬁnal manuscript, questions were often raised as to the
criteria upon which such changes were based. Nevertheless, even here it was assumed that
ﬁnal adjudication by endpoint committees or enhanced ability to carry out a protocol was the
likely explanation for the variations in data in different versions of the results.
Much has changed in the world of academic medicine over the last 35 years. A new focus upon
potential conﬂicts of interest and relations with industry has become part of our daily life.
Competition for scarce research funds or limited academic promotions has blunted some of the
basic trust that existed in the scientiﬁc community. In fact, concerns regarding potential research
misconduct have been borne out by a number of high-proﬁle documented instances of fraudulent
datawithin themedical investigativeﬁeld. The net result has been a less benign view of differences
between preliminary and published versions of research studies, and a greater suspicion of bias.
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1490Investigators whose work exhibits discrepancies between
abstract presentations and the published paper point to the
fact that abstracts are preliminary and that raw data included
in such formats are subjected to additional careful and precise
evaluation, often by core laboratories, before ﬁnal acceptance
and classiﬁcation. They indicate that data from several
different protocolsmay be combined for presentations in order
to provide a picture of the overall status of the work. They
contend that preliminary presentations were never intended to
be deﬁnitive and that data from such versions should be
disregarded when the ﬁnal completed paper is published.
While the above assertions of investigators may well
be true, and might provide a rational explanation for
discrepancies in presented data, they have signiﬁcant
implications regarding the status of abstracts and invited
presentations. Data from abstracts continue to be cited
in published articles and are often incorporated into meta-
analyses. As was recently evidenced in Amsterdam, medical
meetings continue to be enthusiastically attended by
large numbers of physicians, scientists, and healthcare
professionals. The attendees at abstract presentations assume
that the data presented have been carefully gathered and
analyzed, and are accurate. If we were to accept that such
data are preliminary, not fully analyzed and subject to
change, and that all bets were off as to what the ﬁnal pub-
lished paper might report, attendance at such venues would
lose much of its attraction. Therefore, recognizing the
justiﬁable divergence that may occur in data between
(especially the writing of) abstracts and publications, it seems
reasonable to hold investigators responsible for some degree
of accuracy and reproducibility.
So, the issue of discrepancies between abstracts/presentations
and published papers has recently received considerable
attention and provoked some spirited debate. At one extreme,
proponents argue that investigators should be held accountable
for data contained in abstracts and presentations, and that the
existence of differences between those versions and published
data raise the specter of biased analysis. At the other extreme,
proponents maintain that data contained in abstracts and
presentations should be recognized as preliminary and
susceptible to change and that inconsistency with published
manuscripts should be generally ignored. Obviously, the
optimal resolution lies squarely in between these 2 extremes.
It seems to me that it is reasonable to expect differences
between preliminary reports such as abstracts and the ﬁnal
published paper. However, it seems equally reasonable
that investigators should be held to account for such
inconsistencies. I, therefore, believe that authors should
proactively indicate in their manuscripts when such
discrepancies exist and provide an explanation. Some may
argue that an explanation from the authors is inadequate,and that the editors should conduct an investigation to
determine the veracity of the account, including examination
of raw data if necessary. However, there continues to be
the assumption of honesty for investigators, and the
clariﬁcation of divergence of data in a manuscript is really no
different than the presentation of any data in any article. In
addition, editors rarely have the resources to conduct such
investigations, and must rely on the participation of the
home institution. So, not to excuse editors of taking
responsibility for the integrity of the material they publish, I
think investigators should, with infrequent exception, be
assumed innocent and have their explanations accepted. If
the foregoing conditions are agreed to, proactive clariﬁcation
of differences in data between various versions of study
results should allay concerns of readers, strengthen the
conﬁdence in the conclusions, and limit the need for
extensive post-publication explanations.
Parenthetically, similar concern has been directed to
divergence between the data proposed to be included in
research protocols ﬁled in open databases (e.g., clinicaltrials.
gov), and those actually reported in the ﬁnished manuscript.
As with abstracts, it is fully understandable that protocols
may change as experience is gathered and data acquired
while performing the experiments. However, investigators
must take the responsibility to update the protocol
description, and more important, describe the changes that
were made and the rationale for these changes in the ﬁnal
manuscript. Such maneuvers would not only allay concern
and strengthen conﬁdence, but also alleviate the need for
extensive post-publication explanation.
We have been blessed in medicine in that over many years
there have been few major instances of scientiﬁc misconduct
in the medical literature. I may be a Pollyanna, but I
continue to believe that the faith placed in the integrity of
medical investigators has been well justiﬁed. However, as is
apparent from the appearance of blogs such as Retraction
Watch, there is more attention to and suspicion of our
research publications, and more evidence of inaccurate data.
In view of our changing environment, it seems prudent to
explain in detail any divergence between preliminary
presentations and published articles, and between proposed
protocol and reported results, even if the details seem
excessive. As the cliché goes: an ounce of prevention .Address correspondence to:
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